Essais liés8clinical trials
VilleRomelocalisation
PaysItalylocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT01247324

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Ocrelizumab SEP Phase 2 NCT04075266 A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT05123703 Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) ACTIVE_NOT_RECRUITING
Interferon beta-1a SEP Phase 3 NCT01247324 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis COMPLETED
Pozelimab + Cemdisiran Myasthénie Phase 3 NCT05070858 NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT04035005 O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ocrelizumab IV SEP Phase 3 NCT05232825 Ocarina II — A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis COMPLETED
Ocrelizumab SEP Phase 3 NCT04548999 GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING